Company Description
Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products.
The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.
It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution.
In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses.
Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody.
The company was incorporated in 2013 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 2013 |
| IPO Date | Oct 31, 2018 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 919 |
| CEO | Dr. Emily Marine Leproust Ph.D. |
Contact Details
Address: 681 Gateway Blvd. South San Francisco, California 94080 United States | |
| Phone | 800-719-0671 |
| Website | twistbioscience.com |
Stock Details
| Ticker Symbol | TWST |
| Exchange | NASDAQ |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 0001581280 |
| CUSIP Number | 90184D100 |
| ISIN Number | US90184D1000 |
| Employer ID | 46-2058888 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Emily Marine Leproust Ph.D. | Co-Founder, Chairman and Chief Executive Officer |
| Dr. Patrick John Finn Ph.D. | President and Chief Operating Officer |
| Paula Green | Senior Vice President of Human Resources |
| Dr. William Charles Banyai Ph.D. | Senior Vice President of Advanced Development, GM of Data Storage and Director |
| Adam Laponis | Chief Financial Officer |
| Robert F. Werner | Vice President and Chief Accounting Officer |
| Siyuan Chen | Chief Technology Officer |
| Dr. Aaron K. Sato Ph.D. | Chief Scientific Officer |
| Chet Gandhi | Chief Information Officer |
| Dennis Cho | Senior Vice President, Chief Legal Officer and Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 23, 2024 | 144 | Filing |
| Apr 9, 2024 | 144 | Filing |
| Apr 2, 2024 | 144/A | Filing |
| Apr 2, 2024 | 144 | Filing |
| Apr 2, 2024 | 144 | Filing |
| Apr 2, 2024 | 144 | Filing |
| Apr 2, 2024 | 144 | Filing |
| Apr 2, 2024 | 144 | Filing |
| Apr 2, 2024 | 144 | Filing |
| Mar 20, 2024 | 144 | Filing |